Nuvation Bio Inc. (NUVB)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Nuvation Bio Inc. reported revenue of $62.90M, up 699.0% from the prior year. The company ran a net loss, with a net margin of -325.3%. It held $594.82M in total assets against $289.11M in total liabilities.
Key ratios (FY2025)
-338.7%
Operating margin
-325.3%
Net margin
-66.9%
Return on equity
+699.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $62.90M | $7.87M | $0 | — | — | — | — |
| Cost of Revenue | — | $7.08M | $0 | — | — | — | — |
| Gross Profit | — | $795.0K | $0 | — | — | — | — |
| Operating Income | -$213.06M | -$592.63M | -$99.82M | -$119.73M | -$93.32M | -$43.55M | — |
| Net Income | -$204.63M | -$567.94M | -$75.80M | -$104.20M | -$86.85M | -$41.66M | — |
| EPS (Diluted) | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 | — | — |
| Total Assets | $594.82M | $540.63M | $621.48M | $672.14M | $776.15M | $221.79M | — |
| Total Liabilities | $289.11M | $76.84M | $16.36M | $17.07M | $30.15M | $6.71M | — |
| Shareholders' Equity | $305.72M | $463.79M | $605.12M | $655.08M | $746.00M | $215.08M | $117.75M |
| Cash & Equivalents | $164.09M | $35.72M | $42.65M | $101.10M | $132.42M | $29.75M | — |
| Operating Cash Flow | -$173.43M | -$130.41M | -$68.00M | -$96.11M | -$68.19M | -$36.53M | — |
| Shares Outstanding | 337.84M | 337.84M | 219.05M | 218.63M | 217.95M | 149.04M | — |